BRIEF-Concert Pharmaceuticals announces positive data from phase 1 of CTP-656

* Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of Ctp-656, lead candidate for the treatment of cystic fibrosis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.